First-Line Treatment of Proven or Probable Invasive Pulmonary Aspergillosis
Clinical Scenario
This protocol addresses patients with proven or probable invasive pulmonary aspergillosis — a diagnosis established or strongly supported by clinical, radiological, and/or microbiological evidence meeting recognised diagnostic criteria.
Treatment Approach
First-line management is centred on a mould-active triazole as the preferred class of therapy. The specific agent, route of administration, and complete clinical algorithm are detailed in the full protocol.
Complete regimen, agent selection, and sequencing available in the structured protocol →
References
DOI: 10.1183/16000617.0114-2022
- Triazoles (voriconazole, isavuconazole or posaconazole) should be privileged for proven or probable IPA and liposomal amphotericin B for possible IPA to ensure broad coverage including the Mucorales and azole-resistant Aspergillus species.
- While voriconazole is recommended as the first-line therapy of IPA, new azoles (posaconazole, isavuconazole) have demonstrated similar efficacy in randomised clinical trials.
View source ↗